---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-257688"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2022-10-04T23:59:59+00:00"
generated_at: "2026-06-23T05:38:43.168085+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunovant prices $75M stock offering at $6/share to fund IMVT-1402 development

## Summary
- Priced 12.5M shares at $6.00 per share; gross proceeds ~$75M before discounts.
- Investors include Logos Capital, Deep Track Capital, Frazier Life Sciences, TCGX, BVF, and Commodore Capital.
- Net proceeds to accelerate IMVT-1402 development, including a proposed pivotal trial.
- Existing cash plus offering proceeds expected to fund company into H2 2025.
- Offering expected to close Oct 6, 2022; SVB Securities and Truist Securities are joint bookrunners.

## SEC filing metadata
- accession: 0001193125-22-257688
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2022-10-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000119312522257688/0001193125-22-257688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000119312522257688/d391688d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-257688
- JSON: https://secwatch.observer/filing/0001193125-22-257688.json
- Plain text: https://secwatch.observer/filing/0001193125-22-257688.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.